Skip to main content

Search

Reset all filters
327 Result(s)
Sort by

Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction

Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction

Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction
CONTINUUM

CONTINUUM

CONTINUUM, a collaborative project, investigates how digital technology can help healthcare professionals manage complex patient cases at home. Keep reading.
EMPA-KIDNEY trial showed significant benefit of JARDIANCE® (empagliflozin) in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people living with chronic kidney disease

EMPA-KIDNEY trial showed significant benefit of JARDIANCE® (empagliflozin) in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people living with chronic kidney disease

EMPA-KIDNEY, the largest and broadest dedicated SGLT2 inhibitor trial in chronic kidney disease, provides new evidence for patients commonly seen in clinical practice 1,2,3 Phase III trial also demonstrated a 14% statistically significant reduction
Our Stories

Our Stories

Find out more about us by reading our stories. Below are the latest press releases, news stories, and more from our family around the world.
Tomorrow leaders

Tomorrow leaders

We invest in our employees by giving them leadership training that enhances their skills and prepares them for future roles within the organization.
R&D - Transforming tomorrow

R&D - Transforming tomorrow

Manami Tsutsumi, Senior Associate Director in Research & Development describes what it's like working on the cutting edge of pharmaceutical development.
Code of Conduct

Code of Conduct

Our Code of Conduct sets the ethical standards that guides all our business activities. It´s about all of us. Each individual plays a vital role in bringing the Code of Conduct to live.
Financial health

Financial health

We constantly review our salaries to make sure they stay competitive in each market but we also provide wider support for financial health.
COACH Program

COACH Program

The COACH Program addresses the unique needs of people living with heart failur and it's yielding promising results across Ontario. Find out more.